Oxford vaccine trials to resume

Grant Boone
September 13, 2020

"The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees and worldwide regulators", AstraZeneca said.

In an email to NPR Saturday, an AstraZeneca spokesperson said "the company will continue to work with health authorities across the world, including the FDA, and be guided as to when other clinical trials can resume".

The Oxford coronavirus vaccine trials are back on after being suspended for an urgent investigation because a volunteer reportedly suffered potentially risky side effects.

Sir John Bell, 68, who sits on the UK's vaccine taskforce and is also Oxford University's regius professor of medicine, has warned that while the majority of vaccines take around eight years to develop, experts have only been working on a COVID-19 one for "just eight months". This vaccine is now under Phase III of the clinical trial and the Chinese military is presently using this vaccine to vaccinate its soldiers.

The fact that some pharmaceutical companies delegate the risks associated with their vaccines to countries which buy them raises additional questions, the RDIF chief said.

Tropical Storm Sally threatens Florida with forecast to be hurricane by Monday
It's the strongest in terms of winds of six disturbances the center was tracking in the Atlantic Ocean and Gulf of Mexico. Roads may become impassable and some communities may become cutoff from first responders and medical services for a time.

But on Saturday the trial was given the all clear by British regulators to resume following a safety review.

Odoemena said Russia's action also poses a potential health risk, adding that already following Russia's "misstep" is China, which has made a decision to approve Sinovac's COVID-19 vaccine candidate. "We will back our scientists to deliver an effective vaccine as soon as safely possible", he wrote on Twitter.

A laboratory technician supervises capped vials during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, conducted on a high-performance aseptic vial filling line on September 11, 2020, at the Italian biologicsmanufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome. A woman in the United Kingdom trial was diagnosed with multiple sclerosis in July, but that event, which triggered the first pause, was deemed not to be related to the vaccine.

The AZD1222 vaccine uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the Covid-19 coronavirus uses to invade cells. The trial is assessing the efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

Phase III in clinical trial is the phase in which the drug is administered to a large number of people to expand the scope of its study for effectiveness and safety of the drug. The company also announced it was resuming clinical trials in Brazil next Monday after being given the green light there as well.

Other reports by

Discuss This Article